clinical trial · NCT05014672
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Calliditas Therapeutics Suisse SA·phase2·completed·n = 76
Primary Biliary CholangitisLiver StiffnessSetanaxibPlacebo
brief summary
The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).
started
Feb 14, 2022
primary completion
May 31, 2024
completion
Jul 2, 2024
last updated
Apr 24, 2025
official title
TRANSFORM: A 24-week, Randomized, Placebo-controlled, Double-blind, Phase 2b Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol